Press release
Dry Age-related Macular Degeneration Drugs Pipeline 2024 | Belite Bio, Inflammx Therapeutics, Ocugen, OliX Pharmaceuticals, Gensight Biologics, Alkeus Pharmaceuticals, Dobecure, Cognition Therapeutics
Explore our latest breakthroughs in Dry Age-related Macular Degeneration Research. Learn more about our innovative pipeline today! @ Dry Age-related Macular Degeneration Pipeline Outlook [https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Dry Age-related Macular Degeneration Pipeline Report
* August 2024:- Stealth BioTherapeutics Inc.- ReNEW: A Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)
* DelveInsight's Dry Age-related Macular Degeneration pipeline report depicts a robust space with 70+ active players working to develop 80+ pipeline therapies for Dry Age-related Macular Degeneration treatment.
* The leading Dry Age-related Macular Degeneration Companies such as Belite Bio, Inflammx Therapeutics, Ocugen, OliX Pharmaceuticals, Gensight Biologics, Alkeus Pharmaceuticals, Dobecure, Cognition Therapeutics, Aviceda Therapeutics, Galimedix Therapeutics, Mitotech, Annexon, Inc., NGM Biopharmaceuticals, Johnson & Johnson, Lineage Cell Therapeutics, Astellas Pharma, Regenerative Patch Technologies, Hoffmann-La Roche, Boehringer Ingelheim, ONL Therapeutics, and others.
* Promising Dry Age-related Macular Degeneration Therapies such as RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104 , and others.
Stay informed about the cutting-edge advancements in Dry Age-related Macular Degeneration Treatments. Download for updates and be a part of the revolution in cancer care @ Dry Age-related Macular Degeneration Clinical Trials Assessment [https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Dry Age-related Macular Degeneration Emerging Drugs Profile
* Tinlarebant (LBS-008): Belite Bio
LBS-008 is a first-in-class oral therapy that prevents the buildup of toxins (A2E) in the eye that cause Stargardt disease and contribute to atrophic Age-related Macular Degeneration (dry AMD). The toxins are by-products of the eye's visual cycle which are produced from vitamin A. LBS-008 works by reducing and modulating a carrier protein, Retinol-Binding Protein 4 (RBP4) that is to transport vitamin A to the eye. LBS-008 does not directly interfere with the visual cycle, and therefore is unlikely to affect the visual cycle rate. LBS-008 received US and EU orphan drug designation (ODD) in 2017 and 2018, and rare pediatric disease designation (RPD) from the FDA in 2018 for the treatment of Stargardt disease. Currently, the drug is in Phase III stage of its development for the treatment of Dry AMD.
* XIFLAM: Inflammx Therapeutics
Xiflam, an orally administered NLRP3 inflammasome inhibitor with broad application that is formulated as a tablet. InflammX will initially focus on the ophthalmic indications of Diabetic Macular Edema (DME), the intermediate stage of Aged-Related Macular Degeneration (iAMD) and the Geographic Atrophy (GA) form of AMD. Xiflam's unique mechanism of action and its ability to cross the blood-brain and blood-retinal barriers provide a novel therapeutic approach for treating retinal diseases with an orally administered tablet capable of treating both eyes simultaneously. This disruptive technology can provide a much needed clinical alternative for treating the millions of patients with diabetic retinopathy and age-related macular degeneration. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Geographic Atrophy.
* OCU410: Ocugen
OCU410 (AAV-RORA) is a modifier gene therapy product candidate being developed for the treatment of dry age-related macular degeneration (Dry AMD). OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene. Various genes associated with AMD are regulated by RORA. The RORA protein plays an important role in lipid metabolism and demonstrates an anti-inflammatory role, which we believe could be a potential therapeutic candidate for dry AMD based on in-vitro and in-vivo (animal model) studies. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Dry AMD.
* OLX301A: OliX Pharmaceuticals
OLX301A aims to be a first-in-class therapeutics for treating both dry and wet age-related macular degeneration (AMD). The program targets a gene that plays a major role in retinal pigment epithelium (RPE) cell damage. Currently, there are no approved therapies to treat patients with both geographic atrophy (GA) and wet AMD, and one drug approved for GA is with concern regarding its efficacy. OLX301A has the potential to be a novel drug for wet AMD patients who is not responsive to conventional VEGF therapies. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Dry AMD.
* GS030: Gensight Biologics
GS030 is an innovative combination of two complementary components: A gene therapy product encoding a photo activatable channel rhodopsin protein, delivered via a modified AAV2 vector known as AAV2 7m8 and biomimetic goggles that stimulate the engineered retinal cells. GS030 uses optogenetics, a biologic technique that involves the transfer of a gene that encodes for a light-sensitive protein, which in turn causes neuronal cells to respond to light stimulation. GS030 includes a bio-engineered AAV2 gene therapy vector that introduces the gene of a photosensitive protein (to which we have exclusive rights in ontogenetic) into the nucleus of the target cells, in case the retinal ganglion cells, or RGCs. Currently the drug is currently in the preclinical stage of development for the treatment of Dry AMD.
Learn more about Dry Age-related Macular Degeneration Drugs opportunities in our groundbreaking Dry Age-related Macular Degeneration Research and development projects @ Dry Age-related Macular Degeneration Unmet Needs [https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Dry Age-related Macular Degeneration Companies and Therapies
* Stealth BioTherapeutics Inc.: Elamipretide
* Luxa Biotechnology, LLC: RPESC-RPE-4W
* Smilebiotek Zhuhai Limited: QA102
* Gyroscope Therapeutics Limited: GT005
* Novartis Pharmaceuticals: Iptacopan (LNP023)
Dry Age-related Macular Degeneration (Dry-AMD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Discover the latest advancements in Dry Age-related Macular Degeneration Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Dry Age-related Macular Degeneration Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Dry Age-related Macular Degeneration Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Scope of the Dry Age-related Macular Degeneration Pipeline Report
* Coverage- Global
* Dry Age-related Macular Degeneration Companies such as Belite Bio, Inflammx Therapeutics, Ocugen, OliX Pharmaceuticals, Gensight Biologics, Alkeus Pharmaceuticals, Dobecure, Cognition Therapeutics, Aviceda Therapeutics, Galimedix Therapeutics, Mitotech, Annexon, Inc., NGM Biopharmaceuticals, Johnson & Johnson, Lineage Cell Therapeutics, Astellas Pharma, Regenerative Patch Technologies, Hoffmann-La Roche, Boehringer Ingelheim, ONL Therapeutics, and others.
* Dry Age-related Macular Degeneration Therapies- RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104, and others.
* Dry Age-related Macular Degeneration Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Dry Age-related Macular Degeneration Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Dry Age-related Macular Degeneration Pipeline on our website @ Dry Age-related Macular Degeneration Drugs and Companies [https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Dry Age-related Macular Degeneration: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Dry Age-related Macular Degeneration- DelveInsight's Analytical Perspective
* Late Stage Products (Preregistration)
* Abicipar pegol: Molecular Partners
* Late Stage Products (Phase III)
* ALK-001: Alkeus Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Elamipretide: Stealth BioTherapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* AAV.sFH: Aevitas Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Dry Age-related Macular Degeneration Key Companies
* Dry Age-related Macular Degeneration Key Products
* Dry Age-related Macular Degeneration- Unmet Needs
* Dry Age-related Macular Degeneration- Market Drivers and Barriers
* Dry Age-related Macular Degeneration- Future Perspectives and Conclusion
* Dry Age-related Macular Degeneration Analyst Views
* Dry Age-related Macular Degeneration Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: yash bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dry-agerelated-macular-degeneration-drugs-pipeline-2024-belite-bio-inflammx-therapeutics-ocugen-olix-pharmaceuticals-gensight-biologics-alkeus-pharmaceuticals-dobecure-cognition-therapeutics]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dry Age-related Macular Degeneration Drugs Pipeline 2024 | Belite Bio, Inflammx Therapeutics, Ocugen, OliX Pharmaceuticals, Gensight Biologics, Alkeus Pharmaceuticals, Dobecure, Cognition Therapeutics here
News-ID: 3616503 • Views: …
More Releases from ABNewswire
Best ADU Builders in St. Petersburg, FL (2026 Review): Zoning, Cost & Contractor …
A 2026 market review examines how homeowners in St. Petersburg, Florida are evaluating ADU builders under stricter zoning and permitting enforcement. The report compares contractor types, highlights common project failures, and explains why design-build firms are increasingly preferred for compliant accessory dwelling unit construction.
ST. PETERSBURG, FL - January 13, 2026 - As demand for accessory dwelling units (ADUs) continues to rise across St. Petersburg and Pinellas County, homeowners are facing…
How to Draw a Corgi: A Creative Guide to Relaxation and Mindfulness
New Book Confessions of a Corgi Doodler Turns Simple Sketches Into a Philosophy for Creative Living
MARIETTA, GA - The new book Confessions of a Corgi Doodler [https://www.amazon.com/Confessions-Corgi-Doodler-Nancy-Kondos/dp/1966972717/ref=tmm_pap_swatch_0?_encoding=UTF8&dib_tag=se&dib=eyJ2IjoiMSJ9.eK5vqZKYyVTf8-wHEYO8Bw.pJTT3UgaTroxKgcIHzvQiAWCz1FNpLKHBjvk9qWGepE&qid=1765308929&sr=1-1] begins with a single instruction: lose your predictions. Let the pen dance. What follows is not just a guide to drawing the charming, short legged dog, but a series of illustrated revelations on creativity itself. Published by Author's Tranquility Press, this volume by…
Amidst the Silence of Loss A New Voice Emerges
The new book "Live Again: A Widow's Guide to Healing and Recovery" by Alene Maag offers a compassionate and practical resource for the journey through widowhood.
MARIETTA, GA - In the quiet aftermath of a spouse's death, a crushing duality descends: an ocean of private grief and a mountain of public, practical demands. This isolating space now has a thoughtful new companion. "Live Again: A Widow's Guide to Healing and Recovery…
Sams Gas Kicks Off the New Year by Helping Central Florida Residents Plan for Re …
As Central Florida residents begin a new year, Sams Gas is encouraging homeowners and businesses to start 2026 with dependable propane delivery and proactive energy planning. January is an ideal time to review propane usage, schedule routine deliveries, and ensure tanks are prepared for cooler winter nights and the months ahead.
ORLANDO, FL - January 13, 2026 - As Central Florida residents begin a new year, Sams Gas is encouraging homeowners…
More Releases for Dry
Rising Prevalence Of Dry Eye Conditions Boosts Growth In Dry Eye Products Market …
The Dry Eye Products Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Dry Eye Products Market Size During the Forecast Period?
In recent years, there has been a significant expansion in the market size of dry eye products. The market is projected…
Dry Powder Inhalers Market - Breathe Freely: Dry Powder Inhalers Empowering Asth …
Newark, New Castle, USA: The "Dry Powder Inhalers Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Dry Powder Inhalers Market: https://www.growthplusreports.com/report/dry-powder-inhalers-market/8762
This latest report researches the industry structure,…
Dry Eye Market - Advancing Eye Wellness: Dry Eye Solutions Revolutionizing Relie …
Newark, New Castle, USA - new report, titled Dry Eye Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Dry Eye market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Dry Eye market. The report offers an overview of the market, which…
Dry Lubricants Market Size to Hit $ 813.78 Million by 2028 | Dry Lubricants Indu …
According to our experience research team, Dry Lubricants Market was valued at USD 755.42 Million in 2021, and the global Dry Lubricants industry is projected to reach a value of USD 813.78 Million by 2028, at a CAGR of 1.2% during the forecast period 2022-2028
The report is focused on gaining various Dry Lubricants market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining the market growth. Further, the global…
Dry Ice Market In-Depth Analysis | Key Participants Dry Ice Corp., Dry Ice UK Lt …
Demand for dry ice is expected to magnify with the development of dry ice machines industry across the globe. Manufacturers in large multinational organizations and private firms have been contributing prominently in the revenue growth of dry ice market. Dry ice being a cost-effective product is expected to bolster its demand across various applications in the near future. Rising number of fire accidents leads to increasing demand for dry ice,…
Dry Screw Vacuum Pumps
Swam Dry vacuum pumps are the latest development in the vacuum pump industry. They offer a number of advantages over traditional vacuum pump designs. Best process gas blowers. There is “NO OIL / NO WATER” contact with the process vapours, which is why they are considered extremely environmentally friendly.
Visit us for more info - http://swamatics.com/ProductDetails.aspx?prod=Process%20Gas%20Blowers/Gas%20Boosters
The definition of a dry vacuum pump is a pump that does not use any…
